Iberdomide with or without isatuximab after stem cell transplant for multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests whether adding the drug isatuximab to iberdomide maintenance therapy after a stem cell transplant can help keep multiple myeloma from coming back. It is for people who have already had certain standard treatments and have at least a partial response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been treated with a specific combination therapy that includes a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody (like isatuximab or daratumumab).
- You have received at least one high-dose melphalan chemotherapy and an autologous stem cell transplant.
- You have at least a partial response to your previous treatment (your disease has shrunk or stabilized).
- You are 18 years or older and have a good performance status (able to do daily activities with some help).
- You are willing to use effective contraception during the study if you or your partner can become pregnant.
- You do not have certain other medical conditions, like severe heart, liver, or kidney problems, active infections, or other cancers in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two medicines, iberdomide and daratumumab, given as maintenance therapy after an autologous stem cell transplant. It is for people with multiple myeloma who still have small amounts of cancer cells detected after transplant and who have already been treated with a daratumumab-containing regimen.
This Phase 2 study tests whether adding isatuximab and lenalidomide after an autologous stem cell transplant can keep multiple myeloma from coming back when tests show leftover (minimal) disease. If it works, it may improve how long you stay in response.
This study tests a combination of four cancer-fighting drugs (isatuximab, iberdomide, bortezomib, and dexamethasone) followed by a stem cell transplant for people newly diagnosed with multiple myeloma. The goal is to see if this approach can help patients live longer and control their disease better.
This Phase 2 trial tests whether adding isatuximab and lenalidomide as long-term treatment after stem cell transplant can help keep high-risk multiple myeloma under control. It may help some people reduce the chance of the disease coming back after transplant.
This trial studies whether adding ixazomib (an oral drug) to a transplant using your own stem cells can control relapsed multiple myeloma better. It may help by strengthening anti-myeloma treatment after the transplant, aiming to delay disease progression.
This trial tests a combination of three drugs (elotuzumab, iberdomide, and dexamethasone) for multiple myeloma that has come back after treatment with a type of CAR T-cell therapy called ide-cel. It aims to see if this new combination can help people who have already tried several other treatments.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.